Golidocitinib

戈利昔替尼

Report date: 2026/03/13 20:02:36
NME

Base Information

Drug NameGolidocitinib
Drug Alias NameJaupkoGolicitinib高瑞哲NC-0322AZD-4205 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK1
Therapy Area/IndicationsLymphohistiocytosis, HemophagocyticHistiocytosisAnemia, Aplastic +[13] 
Global Approved IndicationsLymphoma, T-Cell, Peripheral
Approved Indications in ChinaLymphoma, T-Cell, Peripheral
Original Approved Country/TerritoryMainland China
Original Approved Date2024/06/18
Country/TerritoryUnited StatesTaiwanThailand +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca PlcDizal (Jiangsu) Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesDizal (Jiangsu) Pharmaceutical Co LtdInstitute Of Hematology & Blood Diseases HospitalBeijing Friendship Hospital Co Ltd +[5] 
Inactive CompaniesShanghai STA Pharmaceutical Product Co Ltd
Active IndicationsLymphohistiocytosis, HemophagocyticHistiocytosisAnemia, Aplastic +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG